The People's Majlis has approved the import of methylphenidate, a medication commonly used in the treatment of Attention-Deficit Hyperactivity Disorder (ADHD), following a unanimous vote by members present.

The decision was made after parliament approved the removal of methylphenidate from the list of prohibited substances under Maldivian law. The matter was submitted to parliament following a decision by the Cabinet to address concerns regarding access to ADHD medication for children in the Maldives.

The Cabinet reached the decision after reviewing recommendations made by the National Drug Control Council. In a letter sent to parliament and signed by President Dr Mohamed Muizzu, the Government requested parliamentary approval to amend the list of banned substances under the Drugs Act.

The issue was later reviewed by the Parliamentary Committee on National Security Services, where members unanimously approved the proposal before it was forwarded to the full parliament for a final decision. The matter had also been raised earlier by North Galolhu Member of Parliament Mohamed Ibrahim.

Methylphenidate is internationally recognised as a first-line treatment for ADHD, a neurodevelopmental condition commonly diagnosed during childhood. While the medication is classified in many countries as a controlled prescription substance due to the potential for misuse, medical experts have noted its effectiveness in reducing ADHD symptoms when administered under medical supervision.

The medication had previously been prohibited from import into the Maldives as it was listed under banned substances in the Drugs Act. Health and advocacy groups, including the Maldives Doctors Association, had previously appealed for its removal from the restricted list to improve treatment access for patients diagnosed with ADHD.